Star Combo Pharma (ASX:S66) Dividend Profile Adds an Income Angle to Its Consumer Health Business

Sonal Goyal

15 September 2026 06:32 PM AEST

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Star Combo Pharma (ASX:S66) provides exposure to the consumer health and wellness sector through vitamins, supplements and skincare products.
The company has maintained a Dividend distribution alongside its growth-focused Business model.
Star Combo operates across domestic and international markets, including Asia.
Future dividend capacity depends on Earnings performance, cash generation and business growth.

Star Combo Pharma Limited (ASX:S66) provides investors with exposure to the consumer health sector while maintaining a dividend-paying profile. The company operates across vitamins, dietary supplements and skincare products, with its business model supported by branded products, Manufacturing capabilities and distribution channels.

The company’s dividend profile reflects the characteristics of a smaller healthcare business, where Shareholder returns are balanced against Investment requirements, market expansion and operating performance.

Dividend Details

Star Combo Pharma has declared a final dividend of approximately 0.3 cents per share, with the payment reported as franked. The shares are scheduled to trade ex-dividend on 13 October 2026, with a Record Date of 14 October 2026 and payment scheduled for 30 October 2026.

The Franked Dividend structure provides eligible shareholders with attached franking credits, reflecting Australian company tax paid on the distributed amount.

Given the company’s smaller market size, investors should refer to official company announcements for the final confirmed dividend amount, franking details and payment timetable.

Consumer Health Business

Star Combo Pharma develops, manufactures and distributes health and wellness products, including vitamins, dietary supplements and skincare products.

The company operates across branded consumer health categories, with products marketed through domestic channels and international markets. Its portfolio includes brands across supplements and personal care products, supported by manufacturing and distribution capabilities.

The consumer health sector continues to benefit from Demand for wellness products, although businesses operating in this market face competition, changing consumer preferences and regulatory requirements.

Growth and Market Exposure

Star Combo Pharma has built its business around consumer health products and expanding market opportunities. Its exposure to international markets provides potential growth opportunities but also introduces additional considerations, including foreign exchange movements, regulatory differences and changes in consumer demand.

The company’s manufacturing capability provides greater involvement across its Supply chain, although smaller healthcare companies may face challenges from larger competitors with greater resources and distribution networks.

Dividend Sustainability

For smaller companies, maintaining dividend payments depends on balancing shareholder returns with investment requirements and financial performance.

Future distributions from Star Combo Pharma will depend on earnings growth, available cash flow, business conditions and Capital allocation decisions. A consistent dividend history can provide income appeal, but smaller companies may experience greater variability in earnings and payout capacity compared with larger established businesses.

Investors assessing the dividend profile may consider profitability trends, cash generation, expansion plans and the company’s ability to maintain sustainable margins.

Key Risks and Outlook

Star Combo Pharma operates in a competitive consumer health environment where regulatory requirements, product demand and market conditions can influence performance.

Key considerations include competition in vitamins and supplements, changes in consumer spending, export market conditions and the company’s ability to continue developing successful products.

The company’s smaller size may also result in greater earnings Volatility compared with larger healthcare businesses. For shareholders, the dividend provides an additional return component, but the longer-term outlook remains linked to the company’s ability to grow its consumer health operations.

FAQs

Q: What dividend has Star Combo Pharma (ASX:S66) declared?

A: Star Combo Pharma has declared a final dividend of approximately 0.3 cents per share, with the payment reported as franked.

Q: When will Star Combo Pharma trade ex-dividend?

A: The company’s shares are scheduled to trade ex-dividend on 13 October 2026, with a record date of 14 October 2026.

Q: When will the Star Combo Pharma dividend be paid?

A: The dividend payment is scheduled for 30 October 2026.

Q: What products does Star Combo Pharma manufacture and distribute?

A: Star Combo Pharma operates in the consumer health sector, developing and distributing vitamins, dietary supplements and skincare products.

Q: What factors influence Star Combo Pharma’s future dividends?

A: Future dividends depend on earnings performance, cash generation, business growth, market conditions and capital allocation decisions.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.